

**ASX RELEASE**

**17 March 2021**

## **AMPLIA COMPLETES SINGLE DOSE STUDY OF AMP945**

**Melbourne, Australia:** Amplia Therapeutics Ltd (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce that it has successfully completed the dosing of subjects in the Single Ascending Dose (SAD) component of the Phase 1 clinical trial of its proprietary focal adhesion kinase (FAK) inhibitor AMP945.

The Single Ascending Dose study involved four cohorts of healthy volunteers. The last cohort of volunteers received the highest single dose of AMP945 administered to date and achieved drug exposures corresponding to the maximum allowable level specified in the trial design. As noted for prior cohorts, the highest single dose AMP945 was found to be well tolerated and no safety concerns were identified.

Last month, Amplia announced that it had started dosing subjects for the Multiple Ascending Dose (MAD) component of its Phase 1 trial. The Company remains on track to complete dosing and report top-line data from this trial in the June quarter. Dr John Lambert, CEO of Amplia commented: “We are very encouraged by the data that is coming in from this Phase 1 clinical study. Our focus is now on completing the trial in a timely manner, fully analysing the data and preparing for future clinical studies in patients with cancer and fibrosis.”

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

### **For Further Information**

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

### **About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).